MedTrace Logo

AI-based Measurements of Tumour Burden in PSMA PET-CT

NCT06363435 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 1500

Last updated 2026-04-28

No results posted yet for this study

Summary

The primary aim of the present study is to evaluate how automatically calculated (by an AI-based method) tumour burden, measured as tumour volume (TV) and as tumour uptake (TU: TV x SUVmean) in the prostate/prostate bed, pelvic lymph nodes, distant lymph nodes, bone and as the total tumour burden predicts overall survival (OS) in patients with prostate cancer (newly diagnosed and patients with biochemical recurrence).

Conditions

Interventions

DEVICE

AI-based detection and quantification of suspected tumour/metastases in PSMA PET/CT scans

Tumour burden will be automatically calculated and stored in a database. The result of the AI-based measurements will not involve the handling of the patients

Sponsors & Collaborators

  • Lund University

    collaborator OTHER

  • Elin Tragardh

    lead OTHER

Eligibility

Min Age
20 Years
Max Age
120 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-03-29
Primary Completion
2031-03-31
Completion
2033-03-31

Countries

  • Sweden

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06363435 on ClinicalTrials.gov